Referred to the House Committee on Energy and Commerce.
This bill requires companies that synthesize or sell nucleic acids or related synthesis equipment to implement buyer verification, purpose screening, and risk-based refusal procedures for high-risk sequences. The Secretary of Commerce must publish guidance, maintain a list of covered high-risk sequences, accept notifications of suspicious buyers, and conduct oversight including inspections and civil enforcement.
Public safety emphasis versus regulatory burden and innovation chill
Relative to its intended legislative type, this bill is a substantive regulatory statute that clearly establishes new duties, enforcement authority, and reporting obligations for entities involved in synthesizing or distributing nucleic acids, while also incorporating recurring reporting and stakeholder consultation requirements.
This bill requires companies that synthesize or sell nucleic acids or related synthesis equipment to implement buyer verification, purpose screening, and risk-based refusal procedures for high-risk sequences.
The Secretary of Commerce must publish guidance, maintain a list of covered high-risk sequences, accept notifications of suspicious buyers, and conduct oversight including inspections and civil enforcement.
The law sets timelines for guidance and lists, mandates independent assessments and recordkeeping, creates confidentiality protections for submissions, and preempts certain state laws.
Moderate technical bipartisan appeal but substantial regulatory complexity, federal preemption, industry concerns, and enforcement design reduce near-term enactment likelihood.
Relative to its intended legislative type, this bill is a substantive regulatory statute that clearly establishes new duties, enforcement authority, and reporting obligations for entities involved in synthesizing or distributing nucleic acids, while also incorporating recurring reporting and stakeholder consultation requirements.
Public safety emphasis versus regulatory burden and innovation chill
These are examples from the analysis, not a ranked list of the most-affected groups.
Public safety emphasis versus regulatory burden and innovation chill
Generally supportive because the bill strengthens biosecurity and oversight of potentially dangerous nucleic acids and benchtop synthesizers.
Appreciates independent assessments, notification requirements, and public reporting to Congress on competitiveness and risks.
May seek stronger worker protections, clearer privacy safeguards, and assurance that research and equitable access are not unduly restricted.
Cautiously favorable: recognizes national security rationale and built-in stakeholder consultation processes.
Values the right-to-cure, covered-process rulemaking, and periodic reporting on competitiveness.
Worries about regulatory burden, implementation clarity, and possible impacts on U.S. biotech competitiveness without mitigations.
Skeptical: views the bill as an expansion of federal regulatory power that may burden innovation and commerce.
Concerned about Commerce Department authority to inspect records, subpoena, and impose large civil penalties.
Worries list publication and oversight could harm commercial competitiveness and technology exportability.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Moderate technical bipartisan appeal but substantial regulatory complexity, federal preemption, industry concerns, and enforcement design reduce near-term enactment likelihood.
The bill has not accumulated any surfaced votes yet.
Public safety emphasis versus regulatory burden and innovation chill
Moderate technical bipartisan appeal but substantial regulatory complexity, federal preemption, industry concerns, and enforcement design r…
Relative to its intended legislative type, this bill is a substantive regulatory statute that clearly establishes new duties, enforcement authority, and reporting obligations for entities involved in synthesizing or dis…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.